Effects of hormone replacement therapy on the circadian pattern of atherothrombotic risk factors

American Journal of Cardiology

Volumn 78, Issue 8, 1996, Pages 876-880

  Katz, Richard J ^a,b   Hsia, Judith ^a   Walker, Pam ^a   Jacobs, Helena ^a   Kessler, Craig ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CIRCADIAN RHYTHM; COMPARATIVE STUDY; DRUG EFFECT; ESTROGEN THERAPY; FAT EMBOLISM; FEMALE; FIBRINOLYSIS; HUMAN; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

CIRCADIAN RHYTHM; EMBOLISM, CHOLESTEROL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FIBRINOLYSIS; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 0030587841     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00460-2     Document Type: Article

References (27)

1. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisier CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwald E, and the MILIS Study Group: Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985;313:1315-1322.
2. Tofler GH, Muller JE, Stone PH, Forman S, Solomon RE, Knatterud GL, Braunwald E. Modifiers of timing and possible triggers of acute myocardial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Study Group. J Am Coll Cardiol 1992;20:1049-1055.
3. Tsementzis SA, Gill GS, Hitchcock ER, Gill SK, Beevers DG. Diurnal variation and activity during the onset of stroke. Neurosurgery 1985;17:901-904.
4. Colantonio D, Casale R, Abruzzo BP, Lorenzetti G, Pasqualetti P. Circadian distribution in fatal pulmonary thromboembolism. Am J Cardiol 1989;64:403-404.
5. Andreotti F, Davies GJ, Hackett DR, Khan MI, de Bart ACW, Aber VR, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988;62:635-637.
6. Grimaudo V, Hauert J, Bachmann F, Kruithof EKO. Diurnal variation of the fibrinolytic system. Thromb Haemost 1988;59:495-499.
7. Huber K, Rose D, Resch I, Schuster E, Glogar DH, Kaindl F, Binder BR. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable angina and myocardial infarction. Thromb Haemost 1988;60:372-376.
8. Kluft C, Lie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast acting inhibitor PAI-1. Thromb Haemost 1988;59:329-332.
9. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989;79:101-106.
10. Bridges AB, McLaren M, Scott NA, Pringle TH, McNeill GP, Belch JJF. Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostaglandin stimulating factor in men with ischemic heart disease. Br Heart J 1993;69:121-124.
11. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
12. Jespersen J, Kluft C. Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. Thromb Haemost 1986;55:388-389.
13. Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemost 1988;60:361-364.
14. Kroon U-B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiole and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994;71:420-423.
15. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
16. Meyers GL, Cooper GR, Winn CL. The Center for Disease Control-National Heart, Lung, Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 1989;9:105-135.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Gilpin EA, Hjalmarson A, Ross J Jr. Subgroups of patients with atypical patterns of symptom onset in acute myocardial infarction. Am J Cardiol 1990;66:7G-11G.
19. Hansen O, Johansson BW, Gullberg B. Circadian distribution of onset of acute myocardial infarction in subgroups from analysis of 10,791 patients treated in a single center. Am J Cardiol 1992;69:1003-1008.
20. Barbash GI, Hod H, Roth A, Miller HI, Rath S, Zahav YH, Modan M, Zivelin A, Laniado S, Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989;64:1231-1235.
21. Kurnik PB. Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 1995;91:1341-1346.
22. Gebara O, Mittleman M, Sutherland O, Lipinska I, Matheney BS, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-1958.
23. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in post menopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
24. Epstein SE, Rosing DR, Brakman P, Redwood DR, Astrup T. Impaired fibrinolytic response to exercise in patients with type IV hyperlipoproteinemia. Lancet 1970;2:631-633.
25. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationship between plasma insulin, triglycerides, body mass index and plasminogen activator inhibitor-1. Diabetes Metab 1987;13:331-336.
26. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987;9:263-268.
27. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993;36:817-825.